TNF and rheumatoid arthritis: These clinical data have confirmed the pathological role of IL-6 in RA (for a review, see [13]) and suggest that this second generation of anti-cytokine therapy may have therapeutical relevance in patients who have a limited response to disease modifying anti-rheumatic drugs or biological agents, such as inhibitors of TNF-α [5].